---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-040837"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2024-09-11T23:59:59+00:00"
generated_at: "2026-05-31T05:23:31.547486+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals appoints Dr. Mikael Dolsten to board

## Summary
- Dr. Mikael Dolsten appointed to board effective September 9, 2024.
- Dolsten is Chief Scientific Officer and President, Pfizer R&D since July 2023.
- Granted options to purchase 27,545 shares (vesting over 3 years) and 22,988 shares (vesting in 1 year) at closing market price.
- Entered standard indemnification agreement with the company.
- No arrangements with other persons or family relationships with directors/officers.

## SEC filing metadata
- accession: 0001140361-24-040837
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2024-09-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036124040837/0001140361-24-040837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036124040837/ef20035750_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-040837
- JSON: https://secwatch.observer/filing/0001140361-24-040837.json
- Plain text: https://secwatch.observer/filing/0001140361-24-040837.txt

## Key facts
- Executive change
  Dr. Mikael Dolsten was appointed as Director at ROCKET PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036124040837/0001140361-24-040837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.